Organization | Health Protection Agency, United Kingdom

Health Protection Agency, United Kingdom Report issue

Government Phase 2 Phase 4

Founded: London United Kingdom (2004)

Status: Defunct (2013)

Organization Overview

First Clinical Trial

2004

NCT00197782

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2010

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 4 Trials (4)

haemophilus influenzae type b conjugate vaccine (HibTITER) (1 trial)

hpv 16/18 vaccine (Cervarix) (1 trial)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

quadrivalent groups a, c, y, and w-135 meningococcal vaccine (Menomune-A/C/Y/W-135) (2 trials)

Drugs in Phase 2 Trials (2)

pneumococcal 7-valent conjugate vaccine (Prevnar) (1 trial)

serogroup B meningococcal vaccine (Bexsero) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Communicable Diseases (Phase 4)

Infections (Phase 4)

Meningitis (Phase 2)

Meningitis, Meningococcal (Phase 2)

Meningococcal Infections (Phase 4)

Papillomavirus Infections (Phase 4)

Pneumococcal Infections (Phase 4)

Pneumonia (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 6